Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has received approval for its initial public offering (IPO) of ordinary shares in RMB and listing on the Sci-Tech Innovation Board [1] Group 1: Company Information - The issuer is Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. [1] - The main underwriter for the IPO is China International Capital Corporation Limited [1] Group 2: Regulatory Approval - The application for the IPO has been approved by the Sci-Tech Innovation Board Committee of the Shanghai Stock Exchange [1] - The registration has been authorized by the China Securities Regulatory Commission (CSRC) under license number 2025〔2296〕 [1] Group 3: Disclosure Information - The prospectus for the IPO is available on the Shanghai Stock Exchange website and other specified platforms [1] - The prospectus can also be accessed at the issuer's location and that of the main underwriter [1]

Core Viewpoint - The new share issuance results of Bai'ao Saitou indicate strong demand from offline investors, while online investors showed a low abandonment rate, reflecting overall positive market sentiment towards the company’s stock [1][2][3] Summary by Category Share Issuance Results - The total number of shares issued by the company was 47.50 million, with an issuance price of 26.68 yuan per share [3] - Online investors subscribed for 11.42 million shares, amounting to 304.68 million yuan, while offline investors subscribed for 27.15 million shares, totaling 724.27 million yuan [2][3] - The abandonment rate for online subscriptions was 0.36%, with 4.12 thousand shares abandoned, amounting to 109.98 thousand yuan [1][2] Subscription Details - The final online issuance volume accounted for 24.13% of the total issuance, with a final online winning rate of 0.028% [3] - Offline investors fully subscribed, and the number of shares abandoned by online investors was fully underwritten by the lead underwriter, representing 0.09% of the total issuance [1][3] Recent Trends in New Share Issuance - In the past month, notable companies with high online subscription abandonment included C China Uranium, Nanfang Digital, and Hai'an Group, with abandonment rates of 0.71%, 0.40%, and 0.38% respectively [3] - Bai'ao Saitou's abandonment rate of 0.36% places it among the companies with lower abandonment rates in recent new share issuances [3]

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 海外監管公告 本公告乃百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條的規定刊發。茲載列本公司於上海證券交易所 網站刊發的《首次公開發行股票並在科創板上市網下初步配售結果及網上中籤結 果公告》，僅供參閱。 网下初步配售结果及网上中签结果公告 保荐人（主承销商）：中国国际金融股份有限公司 特别提示 承董事會命 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 香港，2025年12月2日 於本公告日期，本公司董事會包括董事長、首席執行官兼執行董事沈月雷博士、 執行董事倪健博士及張海超博士；非執行董事魏義良先生、周可祥博士及張蕾娣 ...

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 海外監管公告 本公告乃百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條的規定刊發。茲載列本公司於上海證券交易 所網站刊發的《首次公開發行股票並在科創板上市網上發行申購情況及中籤率公 告》，僅供參閱。 承董事會命 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 香港，2025年12月1日 於本公告日期，本公司董事會包括董事長、首席執行官兼執行董事沈月雷博士、 執行董事倪健博士及張海超博士；非執行董事魏義良先生、周可祥博士及張蕾娣 女士；獨立非執行董事華風茂先生、喻長遠博士及梁曉燕女士。 百奥赛图（北京）医药科技股份有限公司 ...

Core Points - The company Baiaosaitu (688796.SH) announced the final issuance numbers after the activation of the allocation mechanism, with a total of 27,146,498 shares issued offline, accounting for 70.31% of the total issuance after deducting the final strategic placement [1] - The online issuance totaled 11,461,000 shares, representing 29.69% of the total issuance after deducting the final strategic placement [1] - The final online subscription success rate was recorded at 0.02801388% after the allocation mechanism was activated [1]

本报记者 许林艳 破解行业难题 "双引擎平台"构筑核心壁垒 抗体新药研发历程漫长且复杂，其成功高度依赖于两大关键环节：一是获得成药性好、高质量的抗体分 子；二是找到精准的模拟疾病发生并进行药效评价的靶点人源化小鼠模型。针对这两大行业痛点，百奥 赛图经过十余年深耕，构建了全球领先的"双引擎平台"体系，向市场证明了其作为平台型Biotech公司的 独特价值。 一方面，百奥赛图利用自主研发的基因编辑技术，打造了基于全人抗体小鼠RenMice®的"千鼠万抗"真 实全人抗体序列库，已针对1000余个潜在可成药靶点构建超过百万条实验级全人抗体序列，为创新药研 发提供丰富且高度确定的源头分子。 平台覆盖单抗、双抗、双抗-ADC、纳米抗体等多类型药物形式，并持续与合作伙伴一起向AOC、ADC 联合策略及体内CAR-T等前沿疗法延伸。截至2025年上半年，该公司累计签署约300项抗体合作协议， 成为全球抗体药物研发的重要赋能者。 另一方面，百奥赛图自2014年起率先构建全球规模领先的靶点人源化小鼠模型库，突破物种差异带来的 研发瓶颈，为双抗、ADC、核酸药物及细胞疗法等多类型药物提供精准的体内验证工具。该公司已开 发数千种基因 ...

Core Viewpoint - The biotechnology company Baiaosaitu (688796.SH) has launched its IPO on the Shanghai Stock Exchange's STAR Market, with an issue price of 26.68 yuan per share, aiming to raise approximately 1.144 billion yuan through the issuance of 47.5 million new A-shares, representing 10.63% of the company's total share capital [1] Group 1: Company Overview - Baiaosaitu was established in 2009 and is headquartered in Beijing, with branches in China (Haimen, Shanghai), the United States (Boston, San Francisco, San Diego), and Germany (Heidelberg), showcasing strong global expansion capabilities [1] - The company has signed approximately 300 antibody collaboration agreements as of mid-2025, positioning itself as a significant enabler in global antibody drug development [1] - As of June 30, the company has obtained 195 authorized patents and submitted 496 patent applications, creating a solid competitive moat and providing bargaining power in international business development negotiations [1] Group 2: Financial Performance - For the first half of 2025, the company reported revenue of 621 million yuan, a year-on-year increase of 51.5%, and a net profit of 48 million yuan, surpassing the total for the previous year [2] - The operating cash flow has turned positive, demonstrating strong self-sustaining capabilities [2] - Revenue from the humanized mouse business reached 274 million yuan, up 56.1% year-on-year, with a gross margin of 79% [2] - Revenue from antibody molecule transfer and development business amounted to 163 million yuan, reflecting a year-on-year growth of 38% [2] - The company maintained high R&D investment, with R&D expenses reaching 209 million yuan in the first half of 2025, a 29% increase year-on-year [2]

Core Viewpoint - Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. is planning to raise approximately 1.18 billion yuan through its initial public offering (IPO) on the Sci-Tech Innovation Board, with the funds allocated for various drug development projects and working capital [2]. Group 1: Company Overview - Bai'ao Saitou was established in 2009 and operates as a preclinical Contract Research Organization (CRO) and biotechnology company [2]. - As of the signing date of the prospectus, the company is jointly controlled by Shen Yulei and Ni Jian, who hold a combined 26.8665% voting rights and are husband and wife [2]. Group 2: IPO Details - The company plans to issue 47.5 million new shares at an offering price of 26.68 yuan per share, aiming to raise a total of approximately 1.27 billion yuan [2]. - After deducting estimated issuance costs of about 122.95 million yuan (excluding tax), the net proceeds from the IPO are expected to be around 1.14 billion yuan [2]. - The funds will be used for the construction of a drug early-stage research and development service platform, antibody drug research and evaluation projects, preclinical research projects, and to supplement working capital [2].

Core Viewpoint - The company, Bai'ao Saitu, is set to launch an IPO on the Sci-Tech Innovation Board, focusing on gene editing and related services, after previously being listed in Hong Kong as the "first gene editing stock" [1]. Group 1: Company Overview - Bai'ao Saitu operates four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1]. - The company has completed approximately 5,300 customized gene editing projects and developed over 4,300 types of gene-edited animals and cell line models by June 30, 2025 [6]. Group 2: Financial Aspects - The company plans to raise funds for various projects, including 4.54 billion for early drug development services (38.28%), 3.16 billion for antibody drug research and evaluation (26.70%), 1.65 billion for preclinical research (13.92%), and 2.50 billion for working capital (21.10%) [5]. - In the first half of this year, the revenue from model animal sales reached 274 million, accounting for 44.2% of total revenue [7]. Group 3: Human Resources - The number of R&D personnel decreased from 627 at the end of 2022 to 403 by June 30, 2025, a reduction of over 30% due to the completion of a large-scale R&D phase [6]. Group 4: Client Base - The primary clients of Bai'ao Saitu include pharmaceutical R&D, biotechnology companies, and research institutions, with Gilead Sciences, Inc. being the largest client, contributing 88 million in revenue, which is 14.25% of total revenue for the period [7].